Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1992 3
1993 1
1994 3
1995 3
1996 1
1997 4
1998 3
1999 3
2000 4
2001 6
2002 7
2003 10
2004 7
2005 16
2006 13
2007 8
2008 4
2009 9
2010 7
2011 8
2012 6
2013 6
2014 4
2015 4
2016 8
2017 3
2019 3
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

151 results
Results by year
Filters applied: . Clear all
Page 1
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). ...
The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61 …
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Catalá-López F, et al. PLoS Med. 2016 Mar 8;13(3):e1001971. doi: 10.1371/journal.pmed.1001971. eCollection 2016 Mar. PLoS Med. 2016. PMID: 26954482 Free PMC article. Review.
Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Tsai WC, Wu HY, Peng YS, Yang JY, Chen HY, Chiu YL, Hsu SP, Ko MJ, Pai MF, Tu YK, Hung KY, Chien KL. Tsai WC, et al. JAMA Intern Med. 2017 Jun 1;177(6):792-799. doi: 10.1001/jamainternmed.2017.0197. JAMA Intern Med. 2017. PMID: 28288249 Free PMC article. Review.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Brenner BM, et al. N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161. N Engl J Med. 2001. PMID: 11565518 Free article. Clinical Trial.
Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF. Ruospo M, et al. Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2. Cochrane Database Syst Rev. 2017. PMID: 28594069 Free PMC article. Review.
Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials.
Li L, Li L. Li L, et al. Kidney Blood Press Res. 2019;44(3):384-395. doi: 10.1159/000499009. Epub 2019 May 10. Kidney Blood Press Res. 2019. PMID: 31079113 Free article.
Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial.
Viecelli AK, Polkinghorne KR, Pascoe EM, Paul-Brent PA, Hawley CM, Badve SV, Cass A, Hooi LS, Kerr PG, Mori TA, Ong LM, Voss D, Johnson DW, Irish AB; Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group. Viecelli AK, et al. PLoS One. 2019 Mar 26;14(3):e0213274. doi: 10.1371/journal.pone.0213274. eCollection 2019. PLoS One. 2019. PMID: 30913208 Free PMC article. Clinical Trial.
Compared with placebo, fish oil reduced intervention rates (0.82 vs 1.14/1000 patient-days, incidence rate ratio [IRR] 0.72, 95% confidence interval [CI] 0.54-0.97), particularly interventions for acute thrombosis (0.09 vs 0.17/1000 patient-days, IRR 0.53, 95% CI 0. …
Compared with placebo, fish oil reduced intervention rates (0.82 vs 1.14/1000 patient-days, incidence rate ratio [IRR] 0.72, 95% conf …
Long-term effectiveness of a community-based model of care in Māori and Pacific patients with type 2 diabetes and chronic kidney disease: a 4-year follow up of the DElay Future End Stage Nephropathy due to Diabetes (DEFEND) study.
Tan J, Manley P, Gamble G, Collins J, Bagg W, Hotu C, Braatvedt G; DEFEND investigators. Tan J, et al. Intern Med J. 2015 Aug;45(8):843-9. doi: 10.1111/imj.12788. Intern Med J. 2015. PMID: 25872126
Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study.
Corsetti JP, Gansevoort RT, Bakker SJL, Dullaart RPF. Corsetti JP, et al. J Clin Lipidol. 2016 Jul-Aug;10(4):842-850. doi: 10.1016/j.jacl.2016.03.003. Epub 2016 Mar 12. J Clin Lipidol. 2016. PMID: 27578115
151 results
Jump to page